Research Findings from University Hospital Regensburg Update Understanding of Monoclonal Antibodies (Tocilizumab Administration in CAR-T Cell Associated Cytokine Release Syndrome Induces Hypofibrinogenemia).

A recent study conducted at University Hospital Regensburg in Germany investigated the incidence, dynamics, and possible causes of hypofibrinogenemia (low fibrinogen levels) after CAR-T cell therapy. CAR-T cell therapy is a breakthrough treatment for cancer immunotherapy but can cause serious side effects such as cytokine release syndrome (CRS). The study found that hypofibrinogenemia is a common complication of CAR-T cell therapy and is associated with the administration of the Interleukin-6 receptor antagonist (IL6-RA) tocilizumab. Tocilizumab inhibits fibrinogen upregulation, leading to protracted hypofibrinogenemia. The findings highlight the need for close monitoring of fibrinogen levels after tocilizumab treatment. [Extracted from the article]